Last $101.95 USD
Change Today -0.43 / -0.42%
Volume 226.8K
JNJ On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
Sao Paulo
Bogota
As of 9:34 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

johnson & johnson (JNJ) Snapshot

Open
$101.58
Previous Close
$102.38
Day High
$102.00
Day Low
$101.34
52 Week High
11/13/14 - $109.49
52 Week Low
02/4/14 - $86.09
Market Cap
286.6B
Average Volume 10 Days
11.2M
EPS TTM
$5.98
Shares Outstanding
2.8B
EX-Date
02/20/15
P/E TM
17.1x
Dividend
$2.80
Dividend Yield
2.71%
Current Stock Chart for JOHNSON & JOHNSON (JNJ)

johnson & johnson (JNJ) Details

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and women’s health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSON’S, AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LUBRIDERM, NEUTROGENA, RoC, VENDÔME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

126,500 Employees
Last Reported Date: 01/20/15
Founded in 1885

johnson & johnson (JNJ) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.5M
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $842.3K
Group Worldwide Chairman and Member of Execut...
Total Annual Compensation: $2.7M
Worldwide Chairman of Pharmaceuticals, Chief ...
Total Annual Compensation: $952.9K
Vice President, General Counsel and Member of...
Total Annual Compensation: $542.3K
Compensation as of Fiscal Year 2013.

johnson & johnson (JNJ) Key Developments

InsuLine Medical Ltd. Signs Memorandum of Understanding with Johnson and Johnson

InsuLine Medical Ltd. is attracting a great deal of attention after the company reported it had signed a memorandum of understanding with Johnson and Johnson. Under the memorandum of understanding, InsuLine and Johnson and Johnson will cooperate immediately in obtaining regulatory approval for marketing InsuPad, which reduces injected insulin uptake speed in diabetics by near 50%. Johnson and Johnson will also manage registration procedures with the various authorities. Once regulatory approval for marketing is obtained, the parties will negotiate a final binding distribution agreement for each territory, in which Johnson and Johnson will be the sole distributor. In addition to Russia, the agreement will also include Ukraine and other former Soviet Union countries Belarus, Armenia, Azerbaijan, Georgia, Kazakhstan, Kirgizstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan. The registration procedure is likely to take a year.

Johnson & Johnson Provides Earnings Guidance for the Full Year 2015

Johnson & Johnson provided earnings guidance for the full year 2015. The company forecast full-year 2015 earnings ranging from $6.12 to $6.27 per share - well above the $5.52 in adjusted earnings per share it generated for all of 2014.

Johnson & Johnson Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 28, 2014

Johnson & Johnson reported unaudited consolidated earnings results for the fourth quarter and full year ended December 28, 2014. For the quarter, sales to customers were $18,254 million against $18,355 million a year ago. Earnings before provision for taxes on income were $2,703 million against $2,750 million a year ago. Net earnings were $2,521 million against $3,519 million a year ago. Diluted net earnings per share were $0.89 against $1.23 a year ago. Adjusted earnings before provision for taxes and net earnings before provision for taxes on income was $3,925 million against $3,909 million a year ago. Diluted net earnings per share were $1.27 against $1.24 a year ago. For the full year, sales to customers were $74,331 million against $71,312 million a year ago. Earnings before provision for taxes on income were $20,563 million against $15,471 million a year ago. Net earnings were $16,323 million against $13,831 million a year ago. Diluted net earnings per share were $5.70 million against $4.81 million a year ago. Adjusted earnings before provision for taxes and net earnings before provision for taxes on income was $21,195 million against $19,169 million a year ago. Net earnings were $17,105 million against $15,876 million a year ago. Diluted net earnings per share were $5.97 against $5.52 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNJ:US $101.95 USD -0.43

JNJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $23.90 USD -0.18
Merck & Co Inc $61.82 USD -0.27
Novartis AG SFr.91.05 CHF +0.05
Pfizer Inc $31.69 USD -0.14
Roche Holding AG SFr.252.70 CHF 0.00
View Industry Companies
 

Industry Analysis

JNJ

Industry Average

Valuation JNJ Industry Range
Price/Earnings 17.8x
Price/Sales 3.9x
Price/Book 3.7x
Price/Cash Flow 17.4x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JOHNSON & JOHNSON, please visit www.jnj.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.